Noom Med
Consumer psychology platform extended into clinical prescribing
Founded 2008 · New York, NY · Private · Website
Our verdict
Excellent at getting members in the door, weakest here at managing what happens after. Reasonable as a bounded pilot; hard to defend as your primary cost-control strategy.
Scorecard
How it scored
Scored against the published rubric. Weights are fixed before review and identical for every vendor.
Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.
Quality of published results: peer review, sample size, control group, and follow-up duration.
Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.
Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.
PBM, carrier, HRIS, and point-solution interoperability without custom engineering.
Time to first appointment, app quality, care-team continuity, and support responsiveness.
Analysis
What we found
Noom converts members better than anything else in this evaluation, and for some buyers that is the point. The concern is that every structural feature driving that enrollment — low friction, asynchronous intake, minimal gating — also removes the brakes on pharmacy spend. Clinical governance is real but lighter than peers, and the outcomes evidence is not published in a form that permits comparison. The commercial terms are the most buyer-friendly here, which makes a bounded pilot genuinely low-risk.
Strengths
- Best-in-class member acquisition — enrollment rates routinely double those of clinical-first vendors
- Lowest barrier to entry in the set: 250 lives, 12-month term, 30-day out
- The behavioral curriculum is genuinely differentiated and has a long consumer track record
Limitations
- Outcomes reporting is vendor-authored with no published methodology, so it cannot be independently assessed
- Asynchronous-first prescribing is thinner clinical oversight than peers at a similar price
- No meaningful cost-control mechanism — no step therapy, no gating beyond BMI, no risk sharing
Best for
Employers prioritizing reach and enrollment over cost control, or running a first pilot with minimal commitment.
Watch out
High enrollment is a cost risk, not just a win. Model what happens if uptake lands at the top of Noom's range.
The details
Commercial and clinical specifics
The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.
Pricing
- Model
- Per-enrolled-member monthly, with consumer-style tiering
- PMPM range
- $28–$62
- Setup fee
- None
- Medications included
- No
- Performance guarantees
- Engagement guarantees only
Contract
- Minimum lives
- 250
- Term
- 12 months
- Termination notice
- 30 days
Eligibility
- BMI threshold
- BMI ≥ 27
- Prior authorization
- No
- Step therapy
- No
- Comorbidity required
- No
Clinical model
- Prescribes
- Yes
- Care team
- Nurse practitioners, Physician oversight, Behavioral coaches
- Titration protocol
- Asynchronous-first with NP review; synchronous visits available on request
- Off-ramp
- Behavioral maintenance track carried over from the consumer product
- Formulary
- Semaglutide, Tirzepatide, Metformin, Bupropion/naltrexone
Outcomes evidence
- Headline claim
- 4.05% average body-weight loss at 68 weeks against a control group that gained 1.46%, in a randomised controlled trial
- Evidence level
- Peer-reviewed RCTRandomized, controlled, externally reviewed.
- Sample size
- 427 adults in the randomised trial
- Follow-up
- 68 weeks, well beyond the end of the core programme
Sources
- Randomised controlled trial of the Noom Weight programme427 adults; 4.05% loss at 68 weeks versus a 1.46% gain in control
- Noom: members kept losing weight a year after the programmeCompany summary of the 68-week trial result
Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.
Integrations
- PBMs
- CVS Caremark, Express Scripts
- Carriers
- Aetna, Cigna
- HRIS
- Workday, ADP, BambooHR
- Eligibility file
- Flat file, monthly cadence
Formulary
Noom Med by medication
How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
Noom Med Reviews Semaglutide
GLP-1 receptor agonist
First-line, with asynchronous-first intake and nurse-practitioner review. The low-friction pathway that drives Noom's category-leading enrollment also removes most of the brakes on initiation.
Noom Med Reviews Tirzepatide
Dual GIP/GLP-1 receptor agonist
Available first-line on the same asynchronous pathway as semaglutide. Given tirzepatide's efficacy advantage, expect member preference to pull volume here once it is offered without a cost hierarchy.
Noom Med Reviews Metformin
Biguanide
Present in the formulary but not a meaningful gate. Noom's model does not depend on routing members through it before incretin therapy.
Alternatives
Others in consumer-brand clinical
Same category, so these are genuine substitutes rather than different products at different prices.
Legacy weight-management brand with an integrated prescribing arm
- PMPM benchmark
- $30–$68
- Minimum lives
- 500